The purpose of the study is to determine the recommended dose (RD) of lenalidomide (Revlimid)
when administered in association with R-CHOP (rituximab (R), cyclophosphamide, doxorubicin,
vincristine and prednisone).
Drug: Lenalidomide and R-CHOP
We will connect you to the doctor responsible for this trial and help you get more information.
Locations near you
Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Full eligibility criteria for NCT00901615
Ages eligible for Study
18 Years to 70 Years
Genders eligible for Study
Accepts Healthy Volunteers
Patients with one of the following B-cell Lymphoma, CD 20 positive:
Mantle cell, Marginal zone, follicular
Histological transformation from low grade to high grade
Diffuse large B cell
Aged from 18 to 70 years
WHO performance status 0, 1 or 2
Signed inform consent
Life expectancy of ≥ 90 days (3 months).
Females of childbearing potential (FCBP)† must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL not more than 3 days from the start of study drug and must either commit to continued abstinence from heterosexual intercourse or begin one acceptable method of birth control, at least 4 weeks before she starts taking lenalidomide. FCBP must also agree to monthly pregnancy testing and must be counseled at a minimum of every 4 weeks about pregnancy precautions and risks of fetal exposure.
Men must agree not to father a child and agree to use a condom if his partner is of child bearing potential. Men must also be counseled at a minimum of every 4 weeks about pregnancy precautions and risks of fetal exposure.
† A female patient is considered to have childbearing potential unless she meets at least one of the following criteria 1) Age > 50 years and naturally amenorrhoeic for > 1 year (amenorrhoea following cancer therapy does not rule out childbearing potential); or 2) Premature ovarian failure confirmed by a specialist gynaecologist or 3) Previous bilateral salpingo-oophorectomy, or hysterectomy, or 4) XY genotype, turner syndrome, uterine agenesis.
Previous treatment with immunotherapy or chemotherapy except:
Chlorambucil or Cyclophosphamide per os alone during less than 6 months, if stopped more than one year before inclusion
Rituximab alone during less than three months, if stopped more than one year before inclusion
Previous radiotherapy except if localized to one lymph node area
Other type of lymphomas: Burkitt, T cell, lymphocytic, CD 20 negative
Central nervous system or meningeal involvement
Contraindication to any drug contained in the chemotherapy regimen
HIV disease, active hepatitis B or C
Any serious active disease or co-morbid medical condition (according to investigator's decision)
Any of the following laboratory abnormalities :
Absolute neutrophil count (ANC) < 1,500 cells/mm3 (1.5 x 109/L).
Platelet count < 100,000/mm3 (100 x 109/L).
Serum SGOT/AST or SGPT/ALT 5.0 x upper limit of normal (ULN).
Serum total bilirubin > 2.0 mg/dL (34 µmol/L), except in case of hemolytic anemia.
Calculated creatinine clearance (Cockcroft-Gault formula) of < 50 mL /min
Prior history of malignancies other than lymphoma (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast) unless the subject has been free of the disease for ≥ 3 years
Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.
Pregnant or lactating females.
Prior ≥ Grade 3 allergic reaction/hypersensitivity to thalidomide.
Prior ≥ Grade 3 rash or any desquamating (blistering) rash while taking thalidomide.
Subjects with ≥ Grade 2 neuropathy.
Prior use of lenalidomide.
Use of any standard or experimental anti-cancer drug therapy within 28 days of the initiation (Day 1) of study drug therapy.
All locations for NCT00901615
CHU de Dijon
Dijon, France, 21034
Lille, France, 59037
CHU Lyon Sud
Pierre Benite, France, 69310
Centre Henri Becquerel
Rouen, France, 76038
Vandoeuvre les Nancy, France, 54511
View full eligibility
Tris trial is registered with FDA with number: NCT00901615. The sponsor of the trial is Lymphoma Study Association and it is looking for 30 volunteers for the current phase.
Official trial title: A Phase IB Study of Escalating Doses of REVLIMID in Association With R-CHOP (R2-CHOP) in the Treatment of B-cell Lymphoma
1What's a trial
4Get in touch
What's a trial
Not sure you're well informed about clinical trials? Learn more about their benefits, risks and other important details.
Enter your details like condition, age, gender and other preferences and we will show you a list of all relevant clinical trials.
Review the summary of the selected clinical trial and all the locations near you in order to see if it's of interest to you.
Get in touch
You've found an interesting trial? We'll need a bit more information about you so we can connect you to the doctor in charge.
Thank you for applying!
We'll contact you soon with more information.
FindMeCure is constantly improving its search. Take part in it and help millions by filling our patients' survey!